Use of cyclophilin D inhibitors to treat or prevent bone disorders

Abstract

Provided herein are methods of treating or preventing a bone disorder in a subject.

What is claimed is: 
     
       1. A method of treating or preventing a bone disorder in a subject, comprising administering to a subject with or at risk of developing a bone disorder an effective amount of a cyclophilin D inhibitor, wherein the bone disorder is a bone disorder associated with decreased osteogenesis, and wherein the bone disorder is osteoporosis or osteoarthritis. 
     
     
       2. The method of  claim 1 , wherein the cyclophilin D inhibitor is selected from the group consisting of N-methyl-4-isoleucine cyclosporin (NIM811), Debio 025, Sanglifehrin A, cyclosporin A and GW5. 
     
     
       3. The method of  claim 1 , wherein administration of the cyclophilin D inhibitor increases osteogenicity of mesenchymal stem cells in the subject. 
     
     
       4. The method of  claim 1 , wherein administration of the cyclophilin D inhibitor increases mitochondrial function in the subject. 
     
     
       5. The method of  claim 1 , wherein the cyclophilin D inhibitor is selected from the group consisting of N-methyl-4-isoleucine cyclosporin (NIM811), Debio 025, Sanglifehrin A, cyclosporin A and GW5.